Alopecia Universalis Onychodystrophy Vitiligo C2931408
A rare autoimmune disorder causing complete loss of body hair, nail abnormalities, and patches of skin depigmentation. The condition involves multiple body systems and often requires long-term management. Treatment may include topical therapies and immunosuppressants.
Key facts at a glance
- ICD-10
- Q84.9
- ICD-11
- LA00.0
- Body system
- dermatologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(dermatologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Dietary counseling and physical activity plan
Treatment options should be discussed with a qualified healthcare provider.
Janus Kinase (JAK) Inhibitors
Oral medications that inhibit JAK signaling pathways involved in autoimmune hair loss. Emerging evidence supports their use in extensive alopecia unresponsive to conventional therapy.
Systemic Immunosuppressants
Broad immunosuppression using agents such as methotrexate, cyclosporine, or mycophenolate to suppress the autoimmune attack on hair follicles, nails, and melanocytes.
Additional treatment options
Topical Immunotherapy for Alopecia
Contact sensitization therapy to redirect immune response and potentially restore hair growth in affected scalp areas.
medicationSupportive Nail Care Protocol
Regular professional nail care, moisturizing, and protective measures to manage onychodystrophy and reduce secondary nail infections.
lifestylePsychological Support Services
Specialized counseling addressing the profound psychosocial impact of total hair loss, visible vitiligo, and nail changes. May include support groups and cognitive behavioral approaches.
psychologicalWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Alopecia Universalis Onychodystrophy Vitiligo C2931408?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Alonso LC, Martinez MR. International consensus on autoimmune alopecia and associated conditions. Dermatol Ther. 2022.
Patel KP, Chen WI, Nguyen HT. Autoimmune polyglandular syndromes: dermatologic manifestations and management. J Clin Immunol. 2021.
Rivera DG, Thompson SD, Kim JH. JAK inhibitor therapy for severe alopecia universalis: a prospective clinical study. Br J Dermatol. 2023.
Nguyen LM, Anderson KR, Garcia EO. Vitiligo and nail involvement: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2020.
Medication Comparisons
Compare medications used to treat Alopecia Universalis Onychodystrophy Vitiligo C2931408. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy